Replies to post #151794 on Biotech Values

[mcbio]

Also mentioned was the PROC trial with VTX2337, the lead compound for VentiRx. The PR notes that the compound is partnered with CELG and not with ARRY. I need to read up on what the terms are.

Yep. ARRY is still ultimately due royalties if the drug is successful. I don't really know much about this drug or chances for success. It's nice to have another iron in the fire; I just think the MEKs and ARRY-614 are much more important to ARRY. And now I actually feel more confident about 520 given the data, the biomarker, and the reference to discussions with ONXX regarding the drug. Think there is at least a chance for some success with 520 whereas before I didn't really assign much value at all to the drug.